Late Stage Development - Integrated Programs

Late Stage Development - Integrated Programs
Product Description

.Accelerating products through to commercial manufacture - Speed the journey from proof-of-concept to commercial launch. The journey from proof-of-concept to commercial launch can be complex. Speed is critical but it shouldn’t come at the expense of product quality. Creating patient-centric formulations and scaling up from pilot-scale to commercial manufacturing, we help clients turn promising molecules into successful drug products.

Read more Show less

QUOTIENT SCIENCES LIMITED

  • US
  • 2017
    On CPHI since
  • 500 - 999
    Employees
Company types
Academic/Research
Consultancy
Contract Service
Manufacturer/Innovator
View company profile
Categories
more categories Show less
Specifications
  • Supplied from
    United Kingdom; United States
More specifications Fewer specifications
Sales Markets
Show more Show less

QUOTIENT SCIENCES LIMITED

  • US
  • 2017
    On CPHI since
  • 500 - 999
    Employees
Company types
Academic/Research
Consultancy
Contract Service
Manufacturer/Innovator
View company profile

More Products from QUOTIENT SCIENCES LIMITED (4)

  • Candidate Selection - Integrated Programs

    Product Candidate Selection - Integrated Programs

    Selecting the right molecules for development - Quickly identify the best drug candidates. Knowing what it takes to develop a successful drug, we help clients select the best molecules for development. Our unique integration of scientific capabilities enables us to provide a complete assessment o...
  • Early Stage Development - Integrated Programs

    Product Early Stage Development - Integrated Programs

    Accelerating molecules through to proof-of-concept - Simplify early development and accelerate to Proof-of Concept.Proof-of-concept (POC) is a key milestone in the development of a new drug candidate. We understand the transition to POC needs to be fast and cost-effective.With fully integrated capabil...
  • Drug Substance

    Product Drug Substance

    Our streamlined approach to developing drug substance has been shown to reduce manufacturing costs by 50% from preclinical to Phase I.  To best support our customer’s needs, we have made significant investments in technologies and equipment to meet the increasing demand for complex small-scale dr...
  • Formulation Development

    Product Formulation Development

    Quotient Sciences has almost 30 years of experience developing a breadth of pharmaceutical formulations across a range of indications. Our innovative approach to formulation development integrates drug product development with clinical evaluation, combined with our experience with over 1,000 molecules at a...

QUOTIENT SCIENCES LIMITED resources (2)

  • Quotient Sciences acquires UK-based CDMO Arcinova

    News Quotient Sciences acquires UK-based CDMO Arcinova

    With over 40 years of experience and 160 employees, Arcinova provides drug substance, drug product and bioanalysis services to over 200 pharma and biotech customers worldwide
    9 Mar 2021
  • Formulation Development at Quotient

    Technical Data Formulation Development at Quotient

    Quotient Sciences has almost 30 years of experience developing a breadth of pharmaceutical formulations across a range of indications. Our innovative approach to formulation development integrates drug product development with clinical evaluation, combined with our experience with over 1,000 molecules at all stages of drug development.